Eisai is counting on its new cancer drug to eventually bring in more than $1 billion a year, and now, thanks to an early FDA approval, the Japanese drugmaker has a head start on making that a reality.

…read more

Source: Eisai wins an early FDA nod for its self-described cancer blockbuster


0 No comments